A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...

The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.

Health officials would like to remind you that we are entering that time of the year still quaintly known as flu season. That ...

RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren ...

There has been a surge in cases of a deadly virus with more babies admitted to hospital, according to the UK Health Security ...

The UK Health Security Agency warns coughs, colds, flu, and Covid are already on the rise, and now norovirus cases are ...

Flu, COVID-19 and RSV are predicted to cause about as many hospitalizations as last year. Houston experts offer tips for ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

The respiratory syncytial virus (RSV) vaccines were about 80% effective in older adults during the 2023-24 respiratory disease season, which was the first season after the shot was approved in the US, ...

Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and ...

Quebec is rolling out its fall vaccination campaign against respiratory viruses, as contagion levels of COVID-19 and other ...